Race Oncology Ltd (ASX: RAC) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Race Oncology Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $298.00 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 170.28 million
Earnings per share -0.069
Dividend per share N/A
Year To Date Return 113.10%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Race Oncology Ltd (ASX: RAC)
    Latest News

    A man sees some good news on his phone and gives a little cheer.
    Share Gainers

    Why Capitol Health, Infratil, Newmont, and Race Oncology shares are charging higher

    These shares are having a good session. But why?

    Read more »

    A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
    Healthcare Shares

    ASX healthcare stock surges 11% on 'incredibly valuable' FDA news

    Some big news is getting investors excited on Tuesday. What's happening?

    Read more »

    A young women pumps her fists in excitement after seeing some good news on her laptop.
    Share Gainers

    Why Arizona Lithium, Bapcor, Race Oncology, and Tower shares are pushing higher

    These shares are starting the week strongly on Tuesday.

    Read more »

    A man sees some good news on his phone and gives a little cheer.
    Share Gainers

    Why Credit Corp, GUD, Race Oncology, and Spartan Resources shares are rising

    These shares are having a decent session. But why?

    Read more »

    Doctor doing a telemedicine using laptop at a medical clinic
    Healthcare Shares

    2 ASX healthcare shares rocking higher on big news

    This 'spray-on skin' company and cancer-fighting biotech have exciting news for shareholders today.

    Read more »

    a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
    Healthcare Shares

    Guess which ASX All Ords share is surging 16% after announcing a new finance chief

    Is this announcement the real reason for the rise?

    Read more »

    A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
    Share Fallers

    Why Brainchip, Chalice Mining, Perseus, and Race Oncology shares are falling

    These ASX shares are having a tough finish to the year.

    Read more »

    a man raises his fists to the air in joyous celebration while learning some exciting good news via his computer screen in an office setting.
    Share Gainers

    Why Lake Resources, Pro Medicus, Race Oncology, and Universal Store shares are rising today

    Let's take a closer look.

    Read more »

    medical asx share price represented by doctor giving thumbs up
    Healthcare Shares

    This ASX All Ords biotech share is on a 16% tear today

    What's getting investors excited about this biotech?

    Read more »

    A woman jumps for joy with a rocket drawn on the wall behind her.
    Healthcare Shares

    Guess which ASX All Ords share is soaring 12% on a 'key step'

    A positive update is getting investors very excited. What did the company announce?

    Read more »

    In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
    Healthcare Shares

    2 ASX healthcare shares racing higher on positive updates

    These healthcare shares are avoiding the market weakness on Wednesday.

    Read more »

    Rising share price chart.
    Share Gainers

    Why Allkem, IGO, Northern Star, and Race Oncology shares are racing higher

    These ASX shares are ending the week strongly.

    Read more »

    Frequently Asked Questions

    No, Race Oncology does not pay dividends at this time.

    Sydney-headquartered Race Oncology Ltd listed on the ASX on 13 July 2016.

    RAC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Race Oncology Ltd

    Race Oncology Ltd (ASX: RAC) is a clinical-stage global biotechnology company focused on cancer care.

    Race’s lead asset, bisantrene, is a small-molecule anthracene chemotherapeutic. It has demonstrated anti-cancer and cardio-protection effects in 46 clinical trials and around 70 peer-reviewed publications.

    The company is now taking its next-generation bisantrene to new fields of cancer treatment. It is initially focusing on two areas of unmet need: metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML).

    As part of its business strategy and clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway. This follows independent research describing bisantrene as the most potent inhibitor of fat mass and obesity-associated protein (FTO). Dysregulation of RNA (or the over-expression of FTO) has been shown to be a driver of a diverse range of cancers. Race and its partners are now in pre-clinical studies to explore the synergies and impact of bisantrene on FTO regulation.

    RAC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    17 Jun 2024 $1.75 $-0.04 -2.23% 83,613 $1.79 $1.79 $1.72
    14 Jun 2024 $1.79 $-0.08 -4.29% 192,621 $1.86 $1.86 $1.76
    13 Jun 2024 $1.87 $-0.02 -1.06% 605,451 $1.97 $2.02 $1.85
    12 Jun 2024 $1.89 $-0.01 -0.53% 265,216 $1.95 $1.95 $1.82
    11 Jun 2024 $1.90 $0.12 6.72% 572,148 $1.84 $1.95 $1.82
    07 Jun 2024 $1.79 $0.03 1.71% 527,111 $1.79 $1.79 $1.70
    06 Jun 2024 $1.75 $0.18 11.46% 450,938 $1.58 $1.80 $1.58
    05 Jun 2024 $1.57 $-0.03 -1.87% 64,090 $1.59 $1.62 $1.56
    04 Jun 2024 $1.61 $-0.04 -2.42% 133,504 $1.65 $1.67 $1.51
    03 Jun 2024 $1.65 $0.17 11.49% 307,111 $1.48 $1.65 $1.46
    31 May 2024 $1.48 $0.04 2.79% 51,493 $1.42 $1.48 $1.41
    30 May 2024 $1.44 $-0.01 -0.69% 76,033 $1.45 $1.49 $1.43
    29 May 2024 $1.45 $0.04 2.85% 40,033 $1.40 $1.45 $1.36
    28 May 2024 $1.41 $-0.05 -3.42% 111,758 $1.45 $1.45 $1.40
    27 May 2024 $1.46 $0.01 0.69% 82,911 $1.47 $1.51 $1.43
    24 May 2024 $1.45 $-0.01 -0.69% 43,177 $1.46 $1.50 $1.43
    23 May 2024 $1.46 $-0.05 -3.31% 59,033 $1.50 $1.50 $1.46
    22 May 2024 $1.51 $-0.01 -0.66% 131,186 $1.55 $1.57 $1.47
    21 May 2024 $1.52 $0.03 2.01% 94,550 $1.51 $1.53 $1.48
    20 May 2024 $1.49 $-0.06 -3.87% 104,377 $1.56 $1.56 $1.47

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    30 May 2024 Mary Harney Issued 3,510 $5,036
    Issue of options.
    30 May 2024 Mary Harney Exercise 1,170 $877
    Exercise of options.
    30 May 2024 Mary Harney Issued 1,170 $877
    Exercise of options.
    23 May 2024 Phillip(Phil) Lynch Issued 21,457 $16,092
    Exercise of options.
    23 May 2024 Phillip(Phil) Lynch Exercise 21,457 $16,092
    Exercise of options.
    23 May 2024 Phillip(Phil) Lynch Issued 64,371 $93,659
    Issue of options.
    04 Dec 2023 Phillip(Phil) Lynch Issued 21,457 $18,989
    Issue of options.
    04 Dec 2023 Mary Harney Issued 1,170 $1,035
    Issue of options.
    01 Dec 2023 Mary Harney Issued 139,516 $118,588
    Issue of options.
    01 Dec 2023 Peter (Pete) Smith Issued 440,019 $374,016
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Phillip(Phil) R Lynch Non-Executive Director Feb 2023
    Mr Lynch has a career spanning more than 30 years in the Asia Pacific region with Johnson & Johnson. He is an experienced executive and board director, with a background across corporate development, strategy, financial performance, marketing and governance.
    Ms Mary Harney Non-Executive Director Feb 2021
    Ms Harney is the Director of specialist consulting firm Mary Harney Advisory providing leadership, governance and strategic advice across innovation industries such as health, biotech and agriculture. She currently also serves as Chairman of private Australian biotech Oncology One Pty Ltd, a cancer drug discovery company.
    Dr Peter (Pete) Smith Executive Director Jun 2023
    Dr Smith has over 30 years of experience in the pharmaceutical and biotech industry, in therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies. He is currently CEO of private biotechnology company Myrio Therapeutics. Before joining Myrio, he was CEO of publicly listed Australian companies Alchemia and AMRAD. Prior to moving to Australia, Peter co-founded and was CFO of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC, being involved in numerous transactions including LSE/NASDAQ IPOs, fundraisings, and M&A. His undergraduate degree and PhD are from the University of Cambridge. In addition to serving as a Director of Race Oncology, he is also currently a Director of Myrio Therapeutics, MycRx Inc., Hula Therapeutics Inc. and Amala Therapeutics.
    Mr Peter Webse Company Secretary Aug 2016
    Peter Webse Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Dr Daniel Tillett 14,014,370 8.59%
    Mr Phillip Richard Perry 6,047,694 3.71%
    Mr Mark Phillip Juan 5,652,312 3.47%
    Biosynergy Partners Pty Ltd 5,102,194 3.13%
    The Trust Company (Australia) Limited <MOF A/C> 4,450,468 2.73%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 2,648,807 1.62%
    Dr Daniel Tillett (ii) 2,307,925 1.42%
    Craganorig Holdings LLC 2,000,000 1.23%
    Marinella Messina 1,757,377 1.08%
    Mr Phillip Richard Perry & Mrs Tetyana Perry <Doneska Super Fund A/C> 1,600,000 0.98%
    Mr Anthony James Robinson <The Peeko Family No 86 A/C> 1,579,250 0.97%
    Mr Kimberley Ross Gartrell & Mrs Jennifer Margaret Gartrell <K&J Gartrell Super Fund A/C> 1,350,000 0.83%
    Kudoss Investments Pty Ltd <Aitken Global Family A/C> 1,153,034 0.71%
    Mr Kenneth Barry Ridley & Mrs Catherine Mary Ridley <Ridley Retirement Fund A/C> 1,080,000 0.66%
    Mr Sandor Helby 1,060,000 0.65%
    Mr Alan Giles Sauran 1,031,256 0.63%
    Biosynergy Partners Pty Ltd (ii) 1,000,000 0.61%
    Citicorp Nominees Pty Limited 856,443 0.53%
    Mr Van Quy Do 825,788 0.51%
    Mr Brian James Walker 777,777 0.48%